November 02, 2026

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Scrip Code: **530019**

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Bandra-Kurla Complex,
Bandra (E), Mumbai - 400051

Symbol: **JUBLPHARMA**

Sub.: Intimation of Earnings Webinar dated November 16, 2026

Dear Sirs,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the management of the Company shall be organizing an Earnings Webinar on the financial performance of the Company for the Quarter and half year ended September 30, 2026 as per details below:

S. No.	Particulars	Details
1.	Day & Date	Monday, November 16, 2026
2.	Time	08:30 am to 09:30 am (IST)
3.	Venue	-
4.	Participants	All Investors

Note: The presentation made at the aforesaid event will be submitted to the stock exchange, before the event and hosted on the company website at www.jubilantpharmova.com.

This is for your information and record.

Thanking you,

Yours faithfully,
For Jubilant Pharmova Limited

Naresh Kapoor
Digitally signed by Naresh Kapoor
Date: 2026.11.02 18:16:18 +05'30'

Naresh Kapoor
Company Secretary

Encl: As above

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624



EARNINGS WEBINAR
INVITATION

JUBILANT PHARMOVA LIMITED

Earnings Webinar Invitation for Q2 and H1 FY 2027

Monday, November 16, 2026, at 08:30 AM – 09:30 AM IST

08:30 AM IST| 03:00 AM UK | 11:00 AM Singapore | 10:00 PM EST (Sun, Nov15)

The webinar will commence with a brief management commentary on the financial performance for the quarter and half year ended September 30, 2026, followed by an interactive Q&A session.

Registration Details

Pre-registration: Jubilant Pharmova Limited's Q2 & H1 FY27 Earnings Webinar Registration Link

Registration Instructions

- **Platform: Zoom.** Please download the latest app for your device: **Download Link.**
- **Pre-Registration: Mandatory.** Register up to 3 hours before the call using the link.
- **Q&A Session:** After management's commentary, participants may join the queue by clicking the "Raise Hand" icon or post their Questions through chat. When announced, unmute yourself using the "Unmute Me" button to ask your question.

About Jubilant Pharmova Limited

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company with a global presence that is involved in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses. In the Radiopharma business, the Company is involved in the manufacturing and supply of Radiopharmaceuticals with a network of 45 radiopharmacies in the US. The Company's Allergy Immunotherapy business is involved in the manufacturing and supply of allergic extracts and venom products in the US and in some other markets such as Canada, Europe and Australia. Jubilant Pharmova Limited through its CDMO Sterile Injectables business offers manufacturing services for sterile fill and finish injectables (both liquid and lyophilization). The CRDMO business of the Company includes the Drug Discovery Services business that provides contract research and development services through two world-class research centers in Bengaluru and Noida in India and one in France. The CDMO-API business that is involved in the manufacturing of Active Pharmaceutical Ingredients. Jubilant Therapeutics is involved in the Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. The Company operates multiple manufacturing facilities that cater to all the regulated markets including USA, Europe and other geographies. Jubilant Pharmova Limited has a team of around 5,500 multicultural people across the globe. The Company is well recognised as a 'Partner of Choice' by leading pharmaceuticals companies globally.

For more information, please visit: www.jubilantpharmova.com

For more information please contact:

Pankaj Dhawan
Jubilant Pharmova Limited
Ph: +91 120 436 1105
E-mail: Pankaj.dhawan@jubl.com

Runjhun Jain / Sneha Salian
EY Investor Relations
Ph: +91 98207 20993 / +91 98194 30437
E-mail: runjhun.jain@in.ey.com / sneha.salian@in.ey.com

Disclaimer: *Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward- looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.*